IL305079A - Dispersible formulations of N-((R)-3,2-dihydroxypropoxy)-4,3-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and their uses - Google Patents

Dispersible formulations of N-((R)-3,2-dihydroxypropoxy)-4,3-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and their uses

Info

Publication number
IL305079A
IL305079A IL305079A IL30507923A IL305079A IL 305079 A IL305079 A IL 305079A IL 305079 A IL305079 A IL 305079A IL 30507923 A IL30507923 A IL 30507923A IL 305079 A IL305079 A IL 305079A
Authority
IL
Israel
Prior art keywords
fluoro
dihydroxypropoxy
difluoro
iodo
phenylamino
Prior art date
Application number
IL305079A
Other languages
English (en)
Hebrew (he)
Original Assignee
Springworks Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Springworks Therapeutics Inc filed Critical Springworks Therapeutics Inc
Publication of IL305079A publication Critical patent/IL305079A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
IL305079A 2021-02-17 2021-02-17 Dispersible formulations of N-((R)-3,2-dihydroxypropoxy)-4,3-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and their uses IL305079A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/018373 WO2022177555A1 (fr) 2021-02-17 2021-02-17 Formulations dispersibles de n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phénylamino)-benzamide et leurs utilisations

Publications (1)

Publication Number Publication Date
IL305079A true IL305079A (en) 2023-10-01

Family

ID=74859524

Family Applications (1)

Application Number Title Priority Date Filing Date
IL305079A IL305079A (en) 2021-02-17 2021-02-17 Dispersible formulations of N-((R)-3,2-dihydroxypropoxy)-4,3-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and their uses

Country Status (11)

Country Link
EP (1) EP4294525A1 (fr)
JP (2) JP2024507213A (fr)
KR (1) KR20230157314A (fr)
CN (1) CN117279630A (fr)
AR (1) AR124908A1 (fr)
AU (1) AU2021428601A1 (fr)
CA (1) CA3207271A1 (fr)
IL (1) IL305079A (fr)
MX (1) MX2023009559A (fr)
TW (1) TW202245745A (fr)
WO (1) WO2022177555A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322816A (en) 2023-03-16 2025-10-01 Springworks Therapeutics Inc Mirdametinib dosage forms
WO2024192388A1 (fr) * 2023-03-16 2024-09-19 SpringWorks Therapeutics Inc. Formes posologiques de mirdametinib

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
WO2005040098A1 (fr) * 2003-10-21 2005-05-06 Warner-Lambert Company Llc Forme polymorphe du n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
US10034882B2 (en) * 2015-07-27 2018-07-31 Unichem Laboratories Limited Tofacitinib orally disintegrating tablets
WO2018147353A1 (fr) * 2017-02-09 2018-08-16 日本新薬株式会社 Comprimé
KR20230147139A (ko) * 2021-02-17 2023-10-20 스프링웍스 테라퓨틱스, 인크. Mek 저해제인 n-((r)-2,3-다이하이드록시프로폭시)-3,4-다이플루오로-2-(2-플루오로-4-아이오도페닐아미노)-벤즈아마이드의 결정질 고체 및 이의 용도
CN117500781A (zh) * 2021-02-17 2024-02-02 沃尼尔·朗伯有限责任公司 N-((r)-2,3-二羟基丙氧基)-3,4-二氟-2-(2-氟-4-碘-苯氨基)-苯甲酰胺的基本上纯的形式iv的组合物及其用途

Also Published As

Publication number Publication date
CN117279630A (zh) 2023-12-22
CA3207271A1 (fr) 2022-08-25
EP4294525A1 (fr) 2023-12-27
WO2022177555A1 (fr) 2022-08-25
JP2024507213A (ja) 2024-02-16
MX2023009559A (es) 2023-10-25
JP2026004405A (ja) 2026-01-14
AR124908A1 (es) 2023-05-17
AU2021428601A1 (en) 2023-09-28
KR20230157314A (ko) 2023-11-16
TW202245745A (zh) 2022-12-01

Similar Documents

Publication Publication Date Title
US12090128B2 (en) Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereof
US12037306B2 (en) Methods of treating neurofibromatosis type 1 with N-((R))-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
JP2024509759A (ja) Ｍｅｋ阻害剤ｎ－（（ｒ）－２，３－ジヒドロキシプロポキシ）－３，４－ジフルオロ－２－（２－フルオロ－４－ヨード－フェニルアミノ）－ベンズアミドの結晶性固体及びその使用
JP2026004405A (ja) Ｎ－（（ｒ）－２，３－ジヒドロキシプロポキシ）－３，４－ジフルオロ－２－（２－フルオロ－４－ヨード－フェニルアミノ）－ベンズアミドの分散性製剤及びその使用
CN115304593B (zh) 苯并异噻唑化合物及其药物组合物和应用
CN115304590B (zh) 2h-苯并三氮唑衍生物及其制备方法及含有它们的药物组合物
TW202245746A (zh) Ｎ－（（ｒ）－２，３－二羥基丙氧基）—３，４—二氟—２—（２—氟—４—碘—苯基胺基)—苯甲醯胺之基本上純的形式ｉｖ之組合物及其用途
AU2009321385A1 (en) Novel processes and pure polymorphs
AU2009321384A1 (en) Polymorphs
CA3191776A1 (en) Salts of fenfluramine
HK40028824A (en) Polymorphic forms of trimebutine maleate and method of using same